

JUN 6 - 2005

K043296

510 (k) Summary

1. **Date Prepared:** November 15, 2004
2. **Submitter** Covalon Technologies Inc.  
586 Spadina Avenue  
Toronto M5S 2H2  
Ontario, CANADA  
Tel: (416) 944.3496  
Fax: (416) 944.8520  
  
**Submission Correspondent:** Paul L. Guilbaud  
Vice President and Director Wound & Tissue Repair  
Covalon Technologies Inc.  
14510 Kandi Court  
Largo, Florida 33774  
Tel: (727) 595.8184  
Fax: (727) 517.7005  
Email: [pguilbaud@covalon.com](mailto:pguilbaud@covalon.com)
4. **Proprietary Name:** ColActive Ag™ Collagen with Silver, Antimicrobial Dressing  
  
**Common Name:** Wound Dressing
5. **Regulatory Class:** MPG
6. **Statement of Substantial Equivalence:**  
  
ColActive Ag™ Collagen with Silver, Antimicrobial Dressings are substantially equivalent in materials of construction and intended use and identical in function to FIBRACOL PLUS Collagen Wound Dressing with Alginate manufactured by Johnson & Johnson Medical, Vitaphore Silver Foam Wound Dressing manufactured by Vitaphore Corporation and Acticoat Silver Coated Dressing manufactured by Westaim Biomedical, Inc.
7. **Indications For Use:**  
  
ColActive Ag™ Collagen with Silver, Antimicrobial Dressing is indicated for the management of full and partial thickness wounds including:

510 (k) Notification  
ColActive Ag™ Collagen with Silver, Antimicrobial Dressing  
Covalon Technologies, Inc.

- Pressure ulcers
- Diabetic ulcers
- Ulcers caused by mixed vascular etiologies
- Venous ulcers
- First and Second degree burns
- Donor and graft sites
- Abrasions
- Dehisced surgical wounds
- Traumatic wounds healing by secondary intention

**8. Description:**

ColActive Ag™ Collagen with Silver, Antimicrobial Dressing is an advanced wound care dressing composed of collagen, sodium alginate and silver chloride provided in a sterile sheet or rope form. ColActive Ag™ Collagen with Silver, Antimicrobial Dressings are pliable, absorbent dressings that absorb moisture such as wound fluid forming a gel, thus maintaining a moist environment at the wound surface that aids in the formation of granulation tissue and epithelialization. The dressings act as an effective barrier to bacterial and fungal penetration. The silver content is intended to prevent colonization of the dressing. The dressings can be cut to fit specific wounds and are able to be layered for the management of deep wounds."

**9. Biocompatibility:**

ColActive Ag™ Collagen with Silver, Antimicrobial Dressings have been demonstrated to be safe wound dressings. To support the biocompatibility of these products, safety tests were conducted in accordance with ISO 10993 Part 1 Biological Evaluation of Medical Devices.

When all test results from tests conducted on ColActive Ag™ Collagen with Silver, Antimicrobial Dressings are taken into consideration as a whole, ColActive Ag™ Collagen with Silver, Antimicrobial Dressings have been demonstrated to be safe topical wound dressings in accordance with ISO 10993-1.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUN 6 - 2005

Mr. Paul L. Guilbaud  
Vice President and Director of Wound and Tissue Repair  
Covalon Technologies Incorporated  
14510 Kandi Court  
Largo, Florida 33774

Re: K043296  
Trade/Device Name: ColActive Ag<sup>TM</sup> Collagen with Silver, Antimicrobial Dressing  
Regulatory Class: Unclassified  
Product Code: FRO  
Dated: May 20, 2005  
Received: May 23, 2005

Dear Mr. Guilbaud:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Miriam C. Provost', with a stylized flourish at the end.

Miriam C. Provost, Ph.D.

Acting Director

Division of General, Restorative  
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

**PREMARKET NOTIFICATION**  
**INDICATIONS FOR USE STATEMENT**

**510 (k) Number:** k 043296  
Covalon Technologies, Inc.

**Device Name:** ColActive Ag™ Collagen with Silver, Antimicrobial Dressing

**Indications for Use:**

ColActive Ag™ Collagen with Silver, Antimicrobial Dressing is indicated for the management of full and partial thickness including:

- Pressure ulcers
- Diabetic ulcers
- Ulcers caused by mixed vascular etiologies
- Venous ulcers
- First and Second degree burns
- Donor and graft sites
- Abrasions & lacerations
- Dehisced surgical wounds
- Traumatic wounds healing by secondary intention

Prescription Use ☒  
(Per 21 CFR 801.109)

OR Over-the-Counter Use ☐

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

For the Director (Signature)

Director of Center for Restorative

Neurological Devices

25

Number K043296